Porcine Reproductive & Respiratory Syndrome roadmap:
Vaccines
Roadmap for development of a candidate vaccine for PRRSV
Download PRRSV Vaccine Roadmap
---
config:
theme: default
defaultRenderer: 'elk'
themeVariables:
lineColor: "red"
---
flowchart LR
32960["
2
Naturally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine4
Inactivated vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine8
Attenuated organisms3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant4
Inactivated vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
10
Expression system9
Adjuvant11
Vector7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
12
Identity of virulence factors9
Adjuvant12
Identity of virulence factors10
Expression system12
Identity of virulence factors11
Vector13
Identity of virulence factors8
Attenuated organisms13
Identity of virulence factors12
Identity of virulence factors14
Identity of immunomodulators8
Attenuated organisms14
Identity of immunomodulators12
Identity of virulence factors15
Host responses to natural infection8
Attenuated organisms15
Host responses to natural infection12
Identity of virulence factors16
Identity of mechanisms of protection- AAntibody response
- BCell-mediated immunity
12
Identity of virulence factors17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
15
Host responses to natural infection17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
14
Identity of immunomodulators17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
13
Identity of virulence factors17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
16
Identity of mechanisms of protection- AAntibody response
- BCell-mediated immunity
18
Pathogen genome16
Identity of mechanisms of protection- AAntibody response
- BCell-mediated immunity
18
Pathogen genome17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence/ clearance
Lead Summary | Challenges and gap analysis | |
---|---|---|
1 | Vaccine | An improved multivalent PRRSV vaccine preventing disease, virus transmission and carrier state in vaccinated animals |
2D | Efficacy in challenge model | |
2C | Delivery platform | |
2B | Delivery route | |
2A | Safety | |
2 | Naturally attenuated candidates | |
3D | Efficacy in challenge model | |
3C | Delivery platform | |
3B | Delivery route | |
3A | Safety | |
3 | Rationally attenuated candidates | Development of an attenuated vaccine that doesn’t persist or is excreted |
4D | Efficacy in challenge model | |
4C | Delivery platform | |
4B | Delivery route | |
4A | Safety | |
4 | Inactivated vaccines | Development of cross protective/multivalent killed vaccine |
5D | Efficacy in challenge model | |
5C | Delivery platform | |
5B | Delivery route | |
5A | Safety | |
5 | DNA/RNA vaccines | |
6D | Efficacy in challenge model | |
6C | Delivery platform | |
6B | Delivery route | |
6A | Safety | |
6 | Subunit vaccines | Development of a cross protective/multivalent subunit vaccine |
7D | Efficacy in challenge model | |
7C | Delivery platform | |
7B | Delivery route | |
7A | Safety | |
7 | Vectored vaccines | Development of a cross protective/multivalent vectored PRRSV vaccine |
8 | Attenuated organisms | The generation of rationally attenuated genetically modified PRRSV |
9 | Adjuvant | Identifying suitable delivery systems for subunit and inactivated whole virus vaccine candidates |
10 | Expression system | |
11 | Vector | Identifying suitable vector for the expression/delivery of protective PRRSV Antigens |
12 | Identity of virulence factors | Identity of protective antigens |
13 | Identity of virulence factors | To establish the identity of the virulence factors in PRRSV that contribute to disease pathology |
14 | Identity of immunomodulators | To establish the identity of the immunomodulatory factors/stealth mechanisms in PRRSV |
15 | Host responses to natural infection | |
16B | Cell-mediated immunity | |
16A | Antibody response | |
16 | Identity of mechanisms of protection | To identify protective mechanisms in PRRSV infected animals |
17C | Persistence/ clearance | |
17B | Replication | |
17A | Entry | |
17 | Host-pathogen interactions | Host-pathogen interaction in PRRSV infection |
18 | Pathogen genome |